Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: First results from STAMPEDE (MRC PR08, CRUK/06/019), a randomized controlled trial.
Nicholas David James
Research Funding - Janssen-Cilag; Novartis; Pfizer; Sanofi
Matthew Robert Sydes
Research Funding - Janssen-Cilag; Novartis; Pfizer; Sanofi
Malcolm David Mason
Consultant or Advisory Role - Novartis (U); Pfizer (U); Sanofi (U)
Honoraria - Novartis; Pfizer; Sanofi
Research Funding - Janssen-Cilag; Novartis; Pfizer; Sanofi
Noel W Clarke
Research Funding - Janssen-Cilag; Novartis; Pfizer; Sanofi
John Anderson
No relevant relationships to disclose
David Paul Dearnaley
Research Funding - Novartis; Pfizer; Sanofi
John Dwyer
No relevant relationships to disclose
Gordana Jovic
No relevant relationships to disclose
Alastair SW Ritchie
No relevant relationships to disclose
J. Martin Russell
No relevant relationships to disclose
Karen Sanders
No relevant relationships to disclose
George Thalmann
No relevant relationships to disclose
Gianfilippo Bertelli
Consultant or Advisory Role - Pfizer; Sanofi
Honoraria - Novartis; Pfizer; Sanofi
Research Funding - Novartis; Pfizer
Alison J Birtle
Consultant or Advisory Role - Sanofi
Honoraria - Novartis; Pfizer
Research Funding - Novartis; Pfizer
Joe M. O'Sullivan
Consultant or Advisory Role - Janssen-Cilag; Sanofi
Andrew Protheroe
Consultant or Advisory Role - Janssen-Cilag; Pfizer
Denise Sheehan
No relevant relationships to disclose
Narayanan Srihari
Consultant or Advisory Role - Pfizer; Sanofi
Honoraria - Pfizer; Sanofi
Research Funding - Pfizer; Sanofi
Mahesh Parmar
Honoraria - Sanofi
Research Funding - Novartis; Pfizer; Sanofi